Amgen shares are trading higher after the company reported better-than-expected Q2 financial results, raised its FY26 adjusted EPS guidance with its midpoint above estimates and raised its FY26 sales guidance above estimates. Also, BMO Capital maintained its Outperform rating and raised its price target from $400 to $450.